Research programme: breast cancer therapies - Transition TherapeuticsAlternative Names: BCA-901
Latest Information Update: 24 Aug 2010
At a glance
- Originator Transition Therapeutics
- Mechanism of Action Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 15 Mar 2006 Preclinical trials in Breast cancer in Canada (unspecified route)